Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Sariah Liu"'
Autor:
Martin Sattler, Isa Mambetsariev, Jeremy Fricke, Tingting Tan, Sariah Liu, Nagarajan Vaidehi, Evan Pisick, Tamara Mirzapoiazova, Adam G. Rock, Amartej Merla, Sunil Sharma, Ravi Salgia
Publikováno v:
Journal of Clinical Medicine. 12:1936
The development of EGFR small-molecule inhibitors has provided significant benefit for the affected patient population. Unfortunately, current inhibitors are no curative therapy, and their development has been driven by on-target mutations that inter
Autor:
James Shen, Mihaela C. Cristea, Scott Glaser, Christina Hsiao Wei, Daphne Stewart, Siamak Saadat, Edward Wang, Richard Li, Stephen J. Lee, Susan Shehayeb, Ernest S. Han, Thanh H. Dellinger, Sharon P. Wilczynski, Sariah Liu, Lorna Rodriguez-Rodriguez
Publikováno v:
Journal of Clinical Medicine
Journal of Clinical Medicine, Vol 9, Iss 2830, p 2830 (2020)
Journal of Clinical Medicine, Vol 9, Iss 2830, p 2830 (2020)
Epithelial ovarian cancer (EOC) is the most common histology of ovarian cancer defined as epithelial cancer derived from the ovaries, fallopian tubes, or primary peritoneum. It is the fifth most common cause of cancer-related death in women in the Un
Autor:
Laura Kruper, Niki Tank-Patel, Joanne E. Mortimer, Wade Smith, Christina Yeon, Sayeh Moazami Lavasani, Mina S. Sedrak, Tina Wang, Mary Cianfrocca, Yuan Yuan, Sariah Liu, James Waisman, Daphne Stewart
Publikováno v:
Journal of Clinical Medicine; Volume 9; Issue 6; Pages: 1984
Journal of Clinical Medicine, Vol 9, Iss 1984, p 1984 (2020)
Journal of Clinical Medicine
Journal of Clinical Medicine, Vol 9, Iss 1984, p 1984 (2020)
Journal of Clinical Medicine
The development of new HER2-directed therapies has resulted in a significant prolongation of survival for women with metastatic HER2-positive breast cancer. Discoveries in the laboratory inform clinical trials which are the basis for improving the st
Publikováno v:
International Journal of Cancer
Nikanjam, M; Liu, S; & Kurzrock, R. (2016). Dosing targeted and cytotoxic two-drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013. INTERNATIONAL JOURNAL OF CANCER, 139(9), 2135-2141. doi: 10.1002/ijc.30262. UC San Diego: Retrieved from: http://www.escholarship.org/uc/item/008440jz
Nikanjam, M; Liu, S; & Kurzrock, R. (2016). Dosing targeted and cytotoxic two-drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013. INTERNATIONAL JOURNAL OF CANCER, 139(9), 2135-2141. doi: 10.1002/ijc.30262. UC San Diego: Retrieved from: http://www.escholarship.org/uc/item/008440jz
Combining agents has the potential to attenuate resistance in metastatic cancer. However, knowledge of appropriate starting doses for novel drug combinations in clinical trials and practice is lacking. Analysis of 372 published studies was used to as
Autor:
Sariah Liu, Razelle Kurzrock
Publikováno v:
Seminars in Oncology. 42:863-875
Targeted treatments have distinctive side effects: dermatologic problems (rash, hand-food skin reaction, skin/hair whitening), endocrine dysfunction (hyperglycemia, hypothyroidism, dyslipidemia), as well as hypertension, diarrhea, liver problems, ocu
Publikováno v:
Journal of Clinical Medicine
Journal of Clinical Medicine, Vol 9, Iss 1574, p 1574 (2020)
Journal of Clinical Medicine, Vol 9, Iss 1574, p 1574 (2020)
The recent novel coronavirus, named coronavirus disease 2019 (COVID-19), has developed into an international pandemic affecting millions of individuals with hundreds of thousands of deaths worldwide. The highly infectious nature and widespread preval
Dosing Three‐Drug Combinations That Include Targeted Anti‐Cancer Agents: Analysis of 37,763 Patients
Background Combining targeted and cytotoxic agents has the potential to improve efficacy and attenuate resistance for metastatic cancer. Information regarding safe starting doses for clinical trials of novel three-drug combinations is lacking. Materi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2ce7bc3554f3bdc8ee47ea5069e591d
https://europepmc.org/articles/PMC5423521/
https://europepmc.org/articles/PMC5423521/
Publikováno v:
Oncotarget
Metastatic cancers harbor complex genomic alterations. Thus, monotherapies are often suboptimal. Individualized combinations are needed in order to attenuate resistance. To help inform selection of safe starting doses for novel, two-agent, targeted d
Autor:
Razelle Kurzrock, Sariah Liu
Publikováno v:
Cancer treatment reviews. 40(7)
Targeted therapies have unique toxicity profiles. Common adverse events include rash, diarrhea, hypertension, hypothyroidism, proteinuria, depigmentation, and hepatotoxicity. Some of these toxicities are caused by on-target, mechanism-associated effe
Publikováno v:
Journal of Clinical Oncology. 34:2563-2563
2563Background: Metastatic cancers harbor complex genomic alterations. Combinations are needed to attenuate resistance. Knowledge of appropriate starting doses for novel drug combinations in clinic...